Akèy › Glomeruloskleroz fokal segmantè › New York › New York City
Etid klinik pou Glomeruloskleroz fokal segmantè nan New York City, NY
7 etid pou Glomeruloskleroz fokal segmantè ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Ap rekriteFaz 2
- Columbia University Irving Medical Center- Site Number : 8400001, New York
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
Ap rekrite
- Weill Cornell Medicine / NewYork-Presbyterian, New York
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
Ap rekrite
- Weill Cornell Medical Center / NewYork-Presbyterian, New York
NEPTUNE Match Study
Ap rekrite
- Columbia University Medical Center, New York
Nephrotic Syndrome Study Network
Ap rekriteEtid obsèvasyon
- New York University Medical Center, New York
- Bellevue Hospital, New York
- New York University Veterans Administration, New York
- ak 1 plis
AMPK-activation by Metformin in FSGS: AMP-FSGS
Ap rekriteFaz 1/2
- Mount Sinai Hospital, New York
A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB
Ap rekriteFaz 3
- Icahn School of Medicine at Mount Sinai, New York
Etid Glomeruloskleroz fokal segmantè nan lòt vil
- Philadelphia, PA9 etid
- Durham, NC8 etid
- Queens, NY6 etid
- Ann Arbor, MI6 etid
- Los Angeles, CA6 etid
- Miami, FL6 etid
- Atlanta, GA5 etid
- Houston, TX5 etid
- Chicago, IL4 etid
- Cleveland, OH4 etid
- Kansas City, MO4 etid
- Dallas, TX4 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.